

The ALS Association Appoints Vice President for Research

Kuldip Dave, Ph.D. to lead global initiatives for the nation's largest private funder of ALS research

Washington, D.C. (May 30, 2019) — The ALS Association announced today that Kuldip Dave, Ph.D. has been appointed vice president for research, effective May 31. Dr. Dave brings significant experience directing research and drug development programs and managing complex preclinical and clinical programs in the neurodegenerative disease space.

Dr. Dave is a former director of research programs at The Michael J. Fox Foundation for Parkinson's Research, where he developed and implemented the Foundation's ambitious research vision in the biology of Parkinson's. He convened scientists from academe and the pharmaceutical industry to fund promising research opportunities, and he was deeply involved in advancing the study of alpha-synuclein, a protein linked to Parkinson's disease.

"Dr. Dave will lead The ALS Association's global research program, ensuring transparency, accountability and impact across our extensive research portfolio," said Neil Thakur, executive vice president, mission strategy. "In his new capacity, he will ensure that that the Association continues to drive research that improves the lives of people with ALS and helps us find a cure."

Dr. Dave received his undergraduate degree in biology from Rutgers University, and a Ph.D. in pharmacology and physiology from Drexel University College of Medicine. He completed a post-doctoral fellowship at a biotechnology firm and later joined the pharmaceutical company Wyeth, where he was the biology team leader for programs in the Women's Health Department. He later moved to Galleon Pharmaceuticals as a senior research scientist. Dr. Dave lives in Spotswood, New Jersey.

The ALS Association is the nation's leading private source of funding for ALS research. Since the ALS Ice Bucket Challenge five years ago, the Association has committed nearly \$90 million to research. That investment in global research collaborations has led to significant discoveries, including the discovery of five new genes and accelerated the development of new designer DNA drugs targeting the SOD1 and C9orf72 genes.

About ALS

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that afflicts approximately 16,000 people in the United States and a comparable number of patients in Europe. Approximately 5,000 new

cases of ALS are diagnosed each year in the United States. The average life expectancy of an ALS patient is approximately three to five years after diagnosis, and only approximately 10 percent of patients survive for more than 10 years. Death is usually due to respiratory failure because of diminished strength in the skeletal muscles responsible for breathing. Few treatment options exist for these patients, resulting in a high unmet need for new therapies to address functional deficits and disease progression.

About The ALS Association

The ALS Association is the largest private funder of ALS research in the world. The Association funds global research collaborations, provides assistance for people with ALS and their families through our nationwide network of chapters and certified clinical care centers, and advocates for better public policies for people with ALS. The ALS Association builds hope and enhances quality of life while urgently searching for new treatments and a cure. For more information about The ALS Association, visit our website at www.alsa.org.